The FAVOR III Europe study aimed to investigate whether a QFR-based diagnostic strategy yields a non-inferior 12-month clinical outcome compared with an FFR-based strategy.
The findings do not support the use of QFR if FFR is available to guide revascularization decisions in patients with intermediate coronary stenosis.
The ECLIPSE trial evaluated orbital atherectomy (OA) vs conventional balloon dilatation (BA) in patients with de novo severely calcified lesions.
The trial found no difference in target vessel failure (TVF) at one year between the two groups. The minimum stent area at the maximum calcium site was similar, but there was a numerical increase in favor of OA
Several randomized trials have shown reductions in MACE with colchicine in the treatment of coronary artery disease.
The CLEAR SYNERGY (OASIS 9) trial showed that in patients with acute MI undergoing PCI, daily treatment with colchicine did not reduce MACE at 5 years compared with placebo.
